Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447399 | 0.91 | TPMT (0.74) | TPMTMEN1KMT2ACASP6TSHR | |
| SCHEMBL29493652 | 0.91 | TPMT (0.74) | TPMTMEN1KMT2ACASP6TSHR | |
| SCHEMBL10756062 | 0.90 | TPMT (0.72) | TPMTMEN1KMT2ACASP6TSHR | |
| SCHEMBL1190543 | 0.89 | TPMT (0.70) | TPMTMEN1KMT2ACASP6TSHR | |
| SCHEMBL1986869 | 0.86 | TPMT (0.67) | TPMTMEN1KMT2ACASP6TSHR | |
| SCHEMBL29240575 | 0.85 | TPMT (0.61) | TPMTMEN1KMT2ACASP6TSHR | |
| SCHEMBL5216905 | 0.84 | TPMT (0.64) | TPMTMEN1KMT2AMAPTLMNA | |
| SCHEMBL11836249 | 0.83 | TPMT (0.68) | TPMTMEN1KMT2ACASP6TSHR | |
| SCHEMBL8184777 | 0.82 | TPMT (0.62) | TPMTMEN1KMT2ACASP6TSHR | |
| SCHEMBL2896874 | 0.80 | TPMT (0.59) | TPMTMEN1KMT2ACASP6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122054815-A | Optical repair type perovskite photoelectric device and performance repair method thereof | 中核光电科技(上海)有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122054815-A | Optical repair type perovskite photoelectric device and performance repair method thereof | 中核光电科技(上海)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2025067473-A1 | BENZENE RING-CONTAINING COMPOUND HAVING ANALGESIC EFFECT, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川大学华西医院 | 2025-04-03 | — | — | WO | disclosed |
| US-7718576-B2 | Peroxide-based chemiluminescent assays and chemiluminescent compounds used therein | WALDROP III ALEXANDER A | 2010-05-18 | — | — | US | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | TPMT 602/4885MEN1 586/4885KMT2A 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.